Acamprosate - Confluence Pharmaceuticals

Drug Profile

Acamprosate - Confluence Pharmaceuticals

Latest Information Update: 03 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Confluence Pharmaceuticals
  • Developer Indiana University
  • Class Alkanesulfonic-acids; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Autistic disorder; Fragile X syndrome

Most Recent Events

  • 23 Mar 2015 Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals enter into an agreement to co-develop and market acamprosate for fragile X syndrome in Europe and the Middle East
  • 15 Oct 2014 Acamprosate - Confluence Pharmaceuticals receives Orphan Drug status for Fragile X syndrome in European Union
  • 25 Mar 2013 Acamprosate - Confluence Pharmaceuticals receives Orphan Drug status for Fragile X syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top